Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Not Applicable

• Conditions: -E149 Unspecified diabetes mellitus, without complications; Unspecified diabetes mellitus, without complications; E149

• Registration Number: PER-055-04
• Lead Sponsor: BRISTOL MYERS SQUIBB COMPANY,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-09-10
• Last Update Posted: 4 September 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening
HbA1c >or = 7% and < or = 10%
Fasting c-peptide > or = 1.0 umol
Body Mass Index < or = 41 kg/m2
Mean serum triglycerides < or = 600 mg/dl

Exclusion Criteria

1. History of diabetic ketoacidosis, hyperosmolar non-ketotic coma or insulin treatment within one year of selection.
2. Symptomatic type 2 diabetes, defined by polyuria and polydipsia with weight loss greater than 10% during the last three months.
3. History of myocardial infarction (MI), coronary angioplasty, or bypass graft (s), valvular disease or repair, unstable angina, TIA, or cerebrovascular accidents, within six months prior to entering the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified